Join experts from the FDA, Lonza and Simulations Plus for this webinar. They’ll discuss the current status and considerations for dissolution testing of orally inhaled drug products (OIDPs), how modeling and simulation can support development and approval of generic OIDPs, and the importance of incorporating complexity and disease state in pulmonary tissue models of OIDPs.

Attendees will have a chance to participate in a live Q&A at the end.

Presenters:

• Dr. Vinod Shah
  Pharmaceutical Consultant
• Dr. Deanna Mudie
  Principal Scientist in Research and Development, Lonza
• Dr. Elizabeth Bielski
  Senior Pharmacologist, Division of Therapeutic Performance-I (DTP-I), Office of Research and Standards (ORS), Office of Generic Drugs (OGD), Center of Drug Evaluation and Research (CDER) at the FDA
• Dr. Ross Walenga
  Chemical Engineer, Division of Quantitative Methods and Modeling at the Office of Research and Standards
• Dr. James Mullin
  Senior Principal Scientist, Simulations Plus